Pharma R&D unit at Bayer to come under single leadership, with new head

1 December 2017

Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Germany’s Bayer (BAYN: DE) announced today it will further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership.

This unit will combine all R&D activities for therapeutic areas cardiology, gynecology, ophthalmology, hematology as well as oncology research within the company’s pharmaceuticals division.

Joerg Moeller, head of development at Bayer's pharmaceuticals division since February 2014, will become head of research and development effective January 1, 2018.

Andreas Busch, currently head of drug discovery within the pharmaceuticals division of Bayer has decided to pursue a new career opportunity at another company. Dr Busch is taking up the post of head of R&D at Ireland-headquartered Shire (LSE: SHP).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK